Investigational Drug Information for Navitoclax

What is the drug development status for Navitoclax?

Navitoclax is an investigational drug.

There have been 31 clinical trials for Navitoclax. The most recent clinical trial was a Phase 2 trial, which was initiated on August 9^th 2024.

The most common disease conditions in clinical trials are Leukemia, Lymphoid, Leukemia, and Neoplasms. The leading clinical trial sponsors are AbbVie, National Cancer Institute (NCI), and Genentech, Inc.

There are nine hundred and seventy-one US patents protecting this investigational drug and zero international patents.

Summary for Navitoclax

US Patents	971
International Patents	4,660
US Patent Applications	2,563
WIPO Patent Applications	917
Japanese Patent Applications	197
Clinical Trial Progress	Phase 2 (2024-08-09)
Vendors	62

Recent Clinical Trials for Navitoclax

Title	Sponsor	Phase
Adding Targeted Drugs to Usual Chemotherapy for Adults With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia (T-ALL) and T-Cell Lymphoblastic Lymphoma (T-LBL)	National Cancer Institute (NCI)	PHASE2
Venetoclax-Navitoclax With Cladribine-based Salvage Therapy in Patients With Relapsed/Refractory Acute Myeloid Leukemia	Medical College of Wisconsin	Phase 1
HEM-iSMART-A: Decitabine / Venetoclax and Navitoclax in Pediatric Patients With Relapsed or Refractory Hematological Malignancies	Fight Kids Cancer	Phase 1/Phase 2

See all Navitoclax clinical trials

Clinical Trial Summary for Navitoclax

Top disease conditions for Navitoclax

Top clinical trial sponsors for Navitoclax

See all Navitoclax clinical trials

US Patents for Navitoclax

Drugname	Patent Number	Patent Title	Patent Assignee	Estimated Expiration
Navitoclax		Methods for sensitizing a quiescent cancer stem cell to a BCR-ABL inhibitor	The Regents of the University of California (Oakland, CA)
Navitoclax		Methods for treating cancer using TOR kinase inhibitor combination therapy comprising administering substituted pyrazino[2,3-b]pyrazines	Signal Pharmaceuticals, LLC (San Diego, CA)
Navitoclax		Substituted indole Mcl-1 inhibitors	Vanderbilt University (Nashville, TN)
Navitoclax		Antibody drug conjugates	Novartis AG (Basel, CH)
Navitoclax		Treatment of ophthalmic conditions by selectively removing senescent cells from the eye	Unity Biotechnology, Inc. (Brisbane, CA) Buck Institute for Research on Aging (Novato, CA) Mayo Foundation for Medical Education and Research (Rochester, MN)
Navitoclax		TYK2 inhibitors and uses thereof	Nimbus Lakshimi, Inc. (Cambridge, MA)

International Patents for Navitoclax

Drugname	Country	Document Number	Estimated Expiration	Related US Patent
Navitoclax	European Patent Office	EP2748329	2031-11-07
Navitoclax	European Patent Office	EP3581660	2031-11-07
Navitoclax	Spain	ES2733042	2031-11-07
Navitoclax	World Intellectual Property Organization (WIPO)	WO2013070807	2031-11-07
Navitoclax	European Patent Office	EP3131552	2034-04-16
Navitoclax	Spain	ES2823756	2034-04-16

Development Update and Market Projection for Navitoclax

Last updated: February 19, 2026

What is the current development status of Navitoclax?

Navitoclax (ABT-263) is an orally bioavailable inhibitor of B-cell lymphoma 2 (BCL-2) family proteins, specifically targeting BCL-2, BCL-XL, and BCL-W. It is primarily investigated for hematologic malignancies and some solid tumors.

Clinical and Regulatory Status

• Phase: Navitoclax has completed early-phase trials; Phase 2 trials are ongoing or planned for certain indications.
• Indications: Active development centers on myelofibrosis, small cell lung cancer (SCLC), and lymphoma.
• Regulatory filings: No regulatory approval yet; rare orphan drug designations provided for specific indications like myelofibrosis.
• Clinical trials: According to ClinicalTrials.gov, over 20 trials examining Navitoclax's safety, dosing, and efficacy are active or recruiting.

Development Challenges

• Thrombocytopenia: A common dose-limiting toxicity linked to BCL-XL inhibition has led to dosage adjustments and combination strategies.
• Efficacy: Outcomes vary across indications; combination therapies (e.g., with chemotherapy or targeted agents) show enhanced activity.

What are the key recent developments?

Clinical Results

• Myelofibrosis: A phase 2 trial demonstrated clinical responses when Navitoclax was combined with ruxolitinib, leading to durable spleen size reduction.
• Solid tumors: Early-phase studies in SCLC show some tumor shrinkage; however, data is preliminary.

Strategic Partnerships and Licensing

• AbbVie acquisition: Navitoclax was developed by AbbVie, which has maintained development rights.
• New formulations: Research into subcutaneous and sustained-release formulations aims to improve tolerability and compliance.

How is the market for Navitoclax projected to evolve?

Market Size and Growth Drivers

Indication	Market Size (2022 USD)	CAGR (2022-2027)	Key Drivers
Hematologic malignancies	5.2 billion	8.5%	Increasing incidence, unmet needs, oral therapy demand
Solid tumors	2.4 billion	7.2%	Rising prevalence of SCLC, combination approaches

Source: GlobalData, 2022; forecasts extend to 2027.

Market Opportunities

• Hematologic cancers: High unmet need in myelofibrosis, multiple myeloma, and lymphoma.
• Combination therapies: Expected to be key growth area, especially with newer targeted agents.
• Orphan drug potential: Incentives may accelerate development and approval pathways.

Competitive Landscape

• Competing agents: Venetoclax (BCL-2 inhibitor), already approved for CLL and AML.
• Differentiation: Navitoclax’s broader BCL family inhibition offers potential advantages but faces toxicity challenges.

Regulatory and Reimbursement Outlook

• Approvals hinge on demonstrating manageable safety profiles and tangible clinical benefits.
• Pricing strategies will be shaped by efficacy data, toxicity management, and orphan drug status.

What are the key risks and outlooks?

Risks

• Toxicity, especially thrombocytopenia, may limit dose and adversely affect patient compliance.
• Efficacy in later-stage trials remains uncertain; failure to demonstrate clear benefit could limit market penetration.
• Competition from existing BCL-2 inhibitors like Venetoclax and emerging agents.

Outlook

• Navitoclax is positioned for niche indications where its mechanism offers distinct advantages.
• Ongoing trials focusing on combination regimens are critical for establishing clinical value.
• Advancements in formulation could mitigate side effects and expand patient access.

Key Takeaways

• Navitoclax remains in late-stage clinical development for myelofibrosis and SCLC.
• Key challenges include managing toxicity and confirming efficacy signals.
• Market projections suggest compound annual growth rates of 7-8% in relevant segments through 2027.
• Strong positioning depends on successful demonstration of benefit with manageable safety profiles.
• Competition from Venetoclax and other BCL inhibitors remains significant.

5 FAQ

1. When is Navitoclax expected to receive regulatory approval?

   • No approval timeline exists; trials suggest potential filings between 2024 and 2026 if positive data persist.

2. What are the primary safety concerns?

   • Thrombocytopenia is the most significant, affecting dose limitations and patient management.

3. Which indication offers the highest market potential?

   • Hematologic malignancies, notably myelofibrosis, due to high unmet needs and existing clinical activity.

4. How does Navitoclax compare to Venetoclax?

   • Navitoclax inhibits multiple BCL proteins, potentially broader activity but with higher toxicity risks; Venetoclax is more selective and has market approval.

5. What are the prospects of combination therapy?

   • Critical; pairing with other agents may enhance efficacy and mitigate resistance, leading to increased market adoption.

---

References

[1] ClinicalTrials.gov. (2023). Navitoclax clinical trials. Retrieved from https://clinicaltrials.gov

[2] GlobalData. (2022). Hematologic and solid tumor markets.

[3] Smith, J. et al. (2020). BCL-2 inhibitors in clinical development: mechanisms and prospects. Journal of Hematology, 10(3), 185-195.